CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

Abstract Background Dual programmed cell death protein (ligand)-1 (PD-[L]1) and lymphocyte-activation gene-3 (LAG-3) blockade has demonstrated improved anti-tumour response in some advanced solid tumours. CITRINO, a two-part, Phase 1 dose-escalation study, evaluated encelimab (TSR-033; novel anti-LA...

Full description

Saved in:
Bibliographic Details
Main Authors: J. Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y. Chung, Judy Wang, Gerald Falchook, James M. Cleary, Richard Kim, Anuradha Krishnamurthy, Omkar Marathe, Hagop Youssoufian, Catherine Ellis, Angela Waszak, Srimoyee Ghosh, Hailei Zhang, Kaitlin Yablonski, Shruti D. Shah, Ivan Diaz-Padilla, Susanna Ulahannan
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:BJC Reports
Online Access:https://doi.org/10.1038/s44276-024-00118-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44276-024-00118-x

Similar Items